Search

Your search keyword '"Merayo-Lloves, Jesus"' showing total 9 results
Start Over Author "Merayo-Lloves, Jesus" Database OpenAIRE
9 results on '"Merayo-Lloves, Jesus"'

2. Applications of the ImTOPScanner for the investigation of ocular biomechanical parameters

Author

Birkenfeld, Judith, Abass, Ahmed, Alexandrov, Sergey, Bronte-Ciriza, David, Curatolo, Andrea, Eliasy, Ashkan, German, James, Ramos, Ana, Hoz, Andrés, Karnowski, Karol, Lopes, Bernardo, Martinez-Enriquez, Eduardo, McAuley, Ryan, Nolan, Andrew, Solarski, Jędrzej, Varea, Alejandra, Villegas, Lupe, Elsheikh, Ahmed, Leahy, Martin, Merayo-Lloves, Jesus, Wojtkowski, Maciej, and Marcos, Susana

Published
2021

4. Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy

Author

Villatoro, Antonio J., Fernandez, Viviana, Claros, Silvia, Alcoholado, Cristina, Cifuentes, Manuel, Merayo-Lloves, Jesus, Andrades, Jose A., Becerra, Jose, [Villatoro, Antonio J.] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Fernandez, Viviana] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Claros, Silvia] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Alcoholado, Cristina] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Cifuentes, Manuel] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Andrades, Jose A.] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Becerra, Jose] Univ Malaga, Dept Cell Biol Genet & Physiol, IBIMA, E-29071 Malaga, Spain, [Claros, Silvia] CIBER, BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Malaga 29071, Spain, [Alcoholado, Cristina] CIBER, BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Malaga 29071, Spain, [Cifuentes, Manuel] CIBER, BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Malaga 29071, Spain, [Andrades, Jose A.] CIBER, BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Malaga 29071, Spain, [Becerra, Jose] CIBER, BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Malaga 29071, Spain, [Merayo-Lloves, Jesus] Fdn Invest Oftalmol, Oviedo 33012, Spain, [Becerra, Jose] Andalusian Ctr Nanomed & Biotechnol BIONAND, Lab Bioingn & Tissue Regenerat, Malaga 29590, Spain, Ministry of Economy and Competitiveness, Ministry Plan, Iniciativa Ingenio, Consolider Program, CIBER Actions, Instituto de Salud Carlos III, and European Regional Development Fund

Subjects
Ocular-surface, Efficacy, regenerative medicine, growth factor, allogenic cell therapy, lacrimal gland, Autologous serum eyedrops, International-society, dry eye, Platelet-rich plasma, Adipose-tissue, Drops, Bone-marrow, Mesenchymal stem-cells, mesenchymal stem cell, keratoconjunctivitis sicca, Stromal cells
Abstract

Dry eye syndrome is a complex and insidious pathology with a high level of prevalence among the human population and with a consequently high impact on quality of life and economic cost. Currently, its treatment is symptomatic, mainly based on the control of lubrication and inflammation, with significant limitations. Therefore, the latest research is focused on the development of new biological strategies, with the aim of regenerating affected tissues, or at least restricting the progression of the disease, reducing scar tissue, and maintaining corneal transparency. Therapies range from growth factors and cytokines to the use of different cell sources, in particular mesenchymal stem cells, due to their multipotentiality, trophic, and immunomodulatory properties. We will review the state of the art and the latest advances and results of these promising treatments in this pathology.

Published
2017

5. Topical Atropine in the Control of Myopia

Author

GALVIS, Virgilio, TELLO, Alejandro, PARRA, M. Margarita, MERAYO-LLOVES, Jesus, LARREA, Jaime, JULIAN RODRIGUEZ, Carlos, and CAMACHO, Paul Anthony

Subjects
Progression, Topical Atropine, Myopia, Review Article
Abstract

Atropine has been used for more than a century to arrest myopia progression. Compelling evidence of its protective effect has been reported in well-designed clinical studies, mainly performed during the last two decades. However, its exact mechanism of action has not been determined. Experimental findings have shown that the mechanism is not related to accommodation, as was thought for decades. A review of the published literature revealed a significant amount of evidence supporting its safety and efficacy at a concentration of 1.0%, and at lower concentrations (as low as 0.01%).

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results